128 related articles for article (PubMed ID: 10490737)
21. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP
Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879
[TBL] [Abstract][Full Text] [Related]
22. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
[TBL] [Abstract][Full Text] [Related]
25. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
26. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
27. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
28. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.
Zomas A; Stefanoudaki K; Fisfis M; Papadaki T; Mehta J
Bone Marrow Transplant; 1998 Jun; 21(11):1163-5. PubMed ID: 9645583
[TBL] [Abstract][Full Text] [Related]
29. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
31. Donor leukocyte infusions for multiple myeloma.
Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
[TBL] [Abstract][Full Text] [Related]
32. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma.
Cabrera R; Díaz-Espada F; Barrios Y; Briz M; Forés R; Barbolla L; Sanjuán I; Regidor C; Peñalver FJ; Fernández MN
Bone Marrow Transplant; 2000 May; 25(10):1105-8. PubMed ID: 10828874
[TBL] [Abstract][Full Text] [Related]
33. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
35. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
36. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
38. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
[TBL] [Abstract][Full Text] [Related]
39. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
Mutis T; Aarts-Riemens T; Verdonck LF
Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
[TBL] [Abstract][Full Text] [Related]
40. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation.
Imoto S; Murayama T; Gomyo H; Mizuno I; Sugimoto T; Nakagawa T; Koizumi T
Bone Marrow Transplant; 2000 Oct; 26(7):809-10. PubMed ID: 11042667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
